Английская Википедия:Conatumumab

Материал из Онлайн справочника
Версия от 00:53, 21 февраля 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Monoclonal antibody}} {{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 460106777 | image = <!-- Monoclonal antibody data --> | type = mab | mab_type = mab | source = u | target = TRAIL-R2 (CD262) <!-- Clinical data --> | tradename = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B /...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity.[1][2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[3][4]

The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.

References

  1. ↑ Шаблон:Cite journal
  2. ↑ Шаблон:Cite journal
  3. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
  4. ↑ National Cancer Institute: Definition of conatumomab

Шаблон:Monoclonals for tumors


Шаблон:Monoclonal-antibody-stub Шаблон:Antineoplastic-drug-stub

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Conatumumab&oldid=14042232